awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1
Q42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
P2860
Q42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2afb2af32a61b98df7e16073a903cf6d838a391c
P2860
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer